Reversal of Cancer by Dual Strategy?


I present herewith a concise historic account of our development of the new technique for cancer therapy: Reversal of Cancer by Dual Strategy. This new method is based on the possible correction of the mitochondrial filamentation defect of tumors plus minor cytotoxicity addressed to the anoxic and fagocitic tumors redoubts, using the administration of the anticancer agents with a chrono-therapeutic emphasis on the patients mobility. Such methods probably will reach patients in the near future with the collaboration of private clinical trials mainly at least in the USA, Europe and Japan. Only the more essential references of this effort are provided.

Share and Cite:

M. Gosalvez, "Reversal of Cancer by Dual Strategy?," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 518-520. doi: 10.4236/jct.2013.42064.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. V. Hsie and T. T. Puck, “Reversion of Hamster Kidney Epithelial Cells with Cyclic AMP,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 68, No. 2, 1971, pp. 358-361. doi:10.1073/pnas.68.2.358
[2] G. S. Johnson, R. H. Friedman and I. Pastan, “Morphological Change of Epithelial Cells after Treatment with Dibutyril Cyclic AMP,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 68, No. 2, 1971, pp. 425-429. doi:10.1073/pnas.68.2.425
[3] C. Friend, W. Scher, J. G. Holland and T. Sato, “Normal Differentiation of Leukemia Cells,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 68, 1971, p. 3678.
[4] T. T. Puck, “Reverse Transformation, Membranes, Cancer and Microfilaments,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 74, No. 10, 1977, pp. 4491-4495. doi:10.1073/pnas.74.10.4491
[5] Y. Honma, T. Kasukabe, J. Okabe and M. Hozumi, “Prolongation of Survival Time of Mice Inoculated with Myeloid Leukemia Cells by Inducers of Normal Differentiation,” Cancer Research, Vol. 39, No. 8, 1978, pp. 3167-3171.
[6] M. Gosálvez, “Bases for the Design of Pharmacological Effectors Acting on Plasma Membrane Receptors,” Biochemical Society Transactions, Vol. 9, No. 1, 1981, pp. 151-152.
[7] M. Gosálvez y Gosálvez, “The Zipper Mechanism,” Madrid, 1982.
[8] M. Gosálvez, C. Vivero and I. Alvarez, “Restoration of ‘Contact Inhibition’ in Tumor Cells in Tissue Culture with Thiazolidin-4-Carboxylic Acid,” Biochemical Society Transactions, Vol. 7, 1979, pp. 191-192.
[9] M. Gosálvez, “Thioproline and Reversal of Cancer,” Lancet, Vol. 321, No. 8333, 1983, p. 1108. doi:10.1016/S0140-6736(83)91947-5
[10] A. Brugarolas and M. Gosálvez, “Treatment of Cancer by an Inducer of Reverse Transformation,” Lancet, Vol. 315, No. 8159, 1980, pp. 68-70. doi:10.1016/S0140-6736(80)90494-8
[11] Editorial, “Reversal of Cancer,” Lancet, Vol. 1, 1983, pp. 799-800.
[12] F. Boccardo, A. Barbieri, L. Canobbio, D. Guarneri, M. Merlano and R. Rossi, “Phase II Trial of Thioproline in Advanced Epidermoid Head and Neck Tumors,” Cancer Treatment Reports, Vol. 66, 1982, p. 585.
[13] P. Alberto, “Thioproline (Norgamem): A Useless Drug in the Treatment of Squamous Cell Carcinoma,” European Journal of Cancer, Vol. 17, No. 9, 1981, pp. 1061-1062. doi:10.1016/S0277-5379(81)80014-4
[14] H. Cortes-Funes, A. Brugarolas and M. Gosalvez, “Quelamycin: A Summary of Phase I Clinical Trials,” Cancer Chemoand Immunopharmacology Recent Results in Cancer Research, Vol. 74, 1980, pp. 200-206. doi:10.1007/978-3-642-81488-4_25
[15] H. Kozlowski, K. Drabent, H. Seysuck and M. Gosalvez, “Mossbauer, Magnetic and Thermogravimetric Studies on Adriamycin Ferric Complexes,” Inorganica Chimica Acta, Vol. 66, 1982, pp. 189-192. doi:10.1016/S0020-1693(00)85811-9
[16] A. Brugarolas and M. Gosalvez, “Preliminary Clinical Results with Norgamem (Thioproline) and Revercan (2-Amino-2-Thiazoline): The First Inducers of Reverse Transformation,” In: Mathe, Bonnadona and Salmon, Eds., Adjuvant Therapies of Cancer, Springer-Verlag, Berlin, 1982, pp. 346-350.
[17] M. Gosálvez, M. Blanco and C. Fernandez, “Synergy between Quelamycin and Thioproline,” Proceedings of the American Association for Cancer Research, San Diego, 20-23 May 1992.
[18] M. Gosalvez, M. Blanco, M. Bueno and R. Balaguer, “Treatment of Leukaemia 1210 Intravenous Transplants with Tumor Modifiers, Redoubt Cytotoxics and Minor Tranquilizers,” In: G. Lubec and G. A. Rosenthal, Eds., Aminoacids. Chemistry, Biology and Medicine, Escom Sciences Publishers, 1990, pp. 704-711.
[19] M. Gosalvez, “Cancer Reversal by Dual Strategy,” Editorial Gober, Madrid, 1992.
[20] M. Gosálvez, “On the Irreproducibility of Thioproline,” Biomedicine & Pharmacotherapy, Vol. 36, No. 8-9, 1982, pp. 387-388.
[21] M. Gosalvez, “Mitochondrial Filamentation: Some Methods of Isolation and Assay,” IOSR Journal of Pharmacy and Biological Sciences, Vol. 4, No. 4, 2012, pp. 37-39. doi:10.9790/3008-0443739
[22] M. Gosalvez, “Metabolic Control of Respiration and Glycolysis of Tumoral Cells,” Advances in Biological Chemistry, Vol. 3, No. 1, 2013, pp. 86-89. doi:10.4236/abc.2013.31011
[23] M. Gosalvez, “Methods to Be Developed for Some First Future Applications for Mitochondrial Filamentation,” Open Journal of Biophysics, Vol. 3, No. 1A, 2013, pp. 51-53. doi:10.4236/ ojbiphy.2013.31A006

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.